Skip to main content
. Author manuscript; available in PMC: 2015 Feb 3.
Published in final edited form as: J Endocrinol Invest. 2011 Sep 23;34(10):801–810. doi: 10.3275/7925

Fig. 5.

Fig. 5

Anabolic and catabolic pathways of PTH on the skeleton. A) PTH decreases SOST/sclerostin expression in osteocytes. Sclerostin functions as a negative regulator of bone formation, and its downregulation by PTH contributes for the PTH-induced osteoanabolism. B) PTH favors bone resorption, mostly by increasing receptor activator of nuclear factor kappa-B ligand (RANKL) and decreasing osteoprotegerin (OPG) expression in osteoblasts, which ultimately leads to an increase in osteoclast formation and activity.